VNVC Vaccine and Biological Manufacturing Plant and Medsintez Pharmaceutical Company (Russia) sign collaboration agreement on technology transfer for advanced biologics manufacturing

Hanoi, September 12, 2025 – VNVC Vaccine and Biological Manufacturing Plant and Medsintez Pharmaceutical Company (Russian Federation) signed a cooperation agreement on comprehensive technology transfer to manufacture next-generation biologics for the treatment of serious acute and chronic diseases. The signing ceremony was witnessed by Russian Minister of Health Mikhail Murashko and Vietnamese Minister of Health Dao Hong Lan.

Previously, in May 2025 in Moscow, under the witness of President Vladimir Putin and General Secretary To Lam, the two ministers signed a cooperation agreement and jointly witnessed VNVC conclude a comprehensive partnership with the Russian Direct Investment Fund (RDIF) – the highest-level representative of Russia’s pharmaceutical research and manufacturing agencies and other healthcare bodies.

In just five months, VNVC has reached a comprehensive technology transfer agreement with Medsintez, a major Russian pharmaceutical company, to soon bring into Vietnam the manufacturing of Russia’s world-class advanced biologics for the treatment of diabetes, obesity, vascular diseases, viral infections, and notably dengue fever.

This agreement is an important step in concretizing the policy of deepening health cooperation between the two countries, while implementing Politburo’s Resolutions 57 and 72 on breakthroughs in science and technology, innovation, and strengthening the protection and improvement of public health, as well as the National Strategy for the Development of Vietnam’s Pharmaceutical Industry to 2030, with a vision to 2045.

Immediately after the signing, Medsintez and VNVC will commence technology transfer for advanced biologics manufacturing at the VNVC Vaccine and Biological Manufacturing Plant; collaborate in research and development, clinical trials for new drugs and vaccines, and distribute Medsintez’s high-quality pharmaceuticals in Vietnam and ASEAN countries.

In the coming period, a wide range of advanced biological products from Medsintez are expected to be transferred for manufacturing at the VNVC Plant, adhering to high international standards, such as: recombinant albumin; recombinant insulin; disposable and reusable insulin pens; diabetes medicines (liraglutide, semaglutide); the anticoagulant heparin (for prevention and treatment of thromboembolic complications leading to stroke, myocardial infarction, and pulmonary embolism); the antiviral Triazavirin; and follicle-stimulating hormone (FSH) for infertility treatment.

Notably, the two sides will discuss collaboration in clinical research on Triazavirin for the treatment of dengue fever, a disease causing hundreds of thousands of cases and dozens of deaths annually in Vietnam. Triazavirin is recommended by the Ministry of Health of the Russian Federation for treating influenza and acute respiratory viral infections in adults, and is the only drug approved for both treatment and prevention of COVID-19, with promising potential for broader antiviral applications. This partnership is expected to enhance Vietnam’s capacity to respond to dengue, as there is currently no specific curative treatment.

In the event, Russian Minister of Health Mikhail Murashko highlighted Russia’s global contributions in healthcare technologies, from oncology and organ transplantation to the development of modern healthcare systems. During the COVID-19 pandemic, Russia supported nearly 70 countries with medicines, experts, and Sputnik vaccines.

“I believe that this cooperation between Vietnam and Russia will yield mutual benefits toward the ultimate goal of protecting public health and elevating the quality of the healthcare system,” he noted.

Minister Dao Hong Lan, on behalf of the Ministry of Health and the people of Vietnam, expressed gratitude for the decades-long support of the Russian Government and Ministry of Health in training doctors, providing medicines and vaccines, transferring modern technologies, and developing healthcare infrastructure. She welcomed collaboration between research institutes, high-tech medical centers, and reputable medical institutions of both countries, opening many practical programs — especially in advanced cancer treatment, and the manufacturing of medicines, vaccines, and medical biologics — which are urgent needs not only for Vietnam and Russia, but also globally.

Mr. Nguyen Ngo Quang, Director of the Department of Science, Technology, and Training (Ministry of Health), noted that the Russian Minister of Health’s visit focused on four cooperation priorities: (1) development of science and technology; (2) training of experts; (3) knowledge sharing and technology transfer; and (4) leveraging traditional medicine in combination with modern techniques. With the expert workforce and modern infrastructure of the Tam Anh – VNVC Healthcare System, Vietnam has a solid foundation to adopt and master advanced medical technologies for drug and vaccine R&D and manufacturing to serve public health.

Mr. Ngo Chi Dung, Chairman and General Director of VNVC Vaccine and Biological Manufacturing Plant, stated: “Partnership with Medsintez is one of the deep collaborations that VNVC and members of our ecosystem — the Tam Anh Research Institute and Tam Anh General Hospital System — will conclude with Russian research institutes, hospitals, and major pharmaceutical companies. These collaborations align with our goal of broad international cooperation with leading global medical centers to gain early access to new medicines, vaccines, and diagnostic-treatment technologies for the people of Vietnam and international patients receiving care in Vietnam. Together with government agencies and healthcare units, the Tam Anh-VNVC ecosystem is striving to realize the Politburo’s Resolutions 57, 28, 68, and 72 on breakthroughs in healthcare for the people, enhancing self-reliance in high-tech pharmaceutical and vaccine manufacturing, contributing to national health security. It is expected that by late 2027, VNVC Vaccine and Biological Manufacturing Plant will begin producing new-generation vaccines and advanced biological drugs from multiple countries right in Vietnam.”

The VNVC-Medsintez agreement not only marks a significant step in VNVC’s international cooperation and integration, but also affirms the capability of Vietnamese enterprises to adopt and master world-leading technologies. It also opens opportunities for Vietnam to gain early access to high-quality biological drugs for infectious and chronic diseases; gradually shorten the path to technological mastery; reduce import costs, move toward domestic supply autonomy; and progress to export, thereby reinforcing Vietnam’s position as a reputable vaccine-and-biologics manufacturing hub in ASEAN.

In May 2025, VNVC also concluded collaboration agreements with the leading biotechnology partners such as the Gamaleya Research Center for Epidemiology and Microbiology and Binnopharm Group (Russia) to promote research, investment, technology transfer, and commercialization of high-tech biological drugs and vaccines, including mRNA cancer vaccines.

Medsintez is one of Russia's leading biotechnology companies with over 20 years of experience in research, development, and manufacturing of pharmaceuticals, medical devices, and active pharmaceutical ingredients that meet international Good Manufacturing Practice (GMP) standards. The company operates a state-of-the-art plant that pioneered the first genetically engineered insulin manufactured in Russia, meeting 100% of domestic therapeutic insulin needs, and develops high-tech products such as recombinant albumin, reproductive hormones, antiviral drugs, antibiotics, and diabetes medicines. With a strong R&D foundation and internationally certified manufacturing capabilities, Medsintez is regarded as a reliable partner in global technology transfer programs.

Vietnam Vaccine Company (VNVC) operates Vietnam's leading vaccination center network with nearly 240 modern centers nationwide, administering tens of millions of high-quality vaccine doses each year to children and adults, having protected public health for nearly a decade. Building on its success in premium vaccination services, VNVC broke ground on the VNVC Vaccine and Biological Manufacturing Plant in Tay Ninh Province in May 2025, with an initial investment of over 2 trillion VND. This strategic project is oriented to become one of the most advanced vaccine and biological manufacturing facilities in the region, built to international GMP standards of the WHO, EU, and U.S. FDA.

Once operational, the plant is expected to supply hundreds of millions of vaccine doses and biological products annually, first meeting domestic demand and then expanding to ASEAN and international markets, further affirming Vietnam’s pioneering role in vaccine and biologics manufacturing.

Amid global imperatives for health security and supply autonomy in medicines and vaccines, the partnership between VNVC and Medsintez not only strengthens comprehensive Vietnam-Russia relations, but also opens opportunities for Vietnam to deeply integrate into the global pharmaceutical and biological value chain, contributing to national and regional health security.

OTHER ARTICLES